Adult vaccines refer to vaccines that are administered to individuals after they attain the age of 18. These vaccines prevent various life-threatening illnesses like influenza, pneumonia, hepatitis, human papilloma virus (HPV), among others. Adult vaccines are administered through subcutaneous or intramuscular injections. Some of the major types of adult vaccines include influenza, pneumonia, shingles, HPV, measles, mumps, and rubella. The need for immunization against preventable life-threatening diseases has been increasing among adults, contributing to the demand for adult vaccines. With rising awareness regarding preventable diseases, the uptake of adult vaccination programs has increased significantly in the recent past.

The Global Adult Vaccines Market is estimated to be valued at US$ 16,790.11 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030.

Key Takeaways
- Key players operating in the adult vaccines market are GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. These key players are focusing on developing new and innovative vaccines to prevent life-threatening illnesses.

- The growing demand for vaccination against preventable diseases among adults is a major factor driving the adult vaccines market. With rising awareness regarding immunization, the uptake of adult vaccination programs has increased significantly worldwide.

- Technological advancements in vaccine production technologies have enabled the development of thermostable and single-dose vaccines. This has improved the accessibility of vaccines in remote areas and made vaccination drives more effective.

Market Trends

- Rising focus on combination vaccines: Combination vaccines simultaneously protect against multiple diseases, reducing the complexity and costs involved in administering separate vaccines. Major players are focusing on developing novel combination vaccines to improve compliance.

- Growing demand for therapeutic vaccines: Therapeutic vaccines are gaining traction for targeting chronic diseases like cancer, neurological disorders, and infectious diseases. Significant R&D investments are being made to develop therapeutic vaccines.

Market Opportunities

- Untapped potential in developing nations: Developing regions like Asia Pacific and Latin America continue to remain undiscovered areas for vaccination due to poor healthcare infrastructure and awareness. Mass immunization programs can drive notable revenues.

- Launch of vaccines targeting novel diseases: Companies are investing in research for vaccines against emerging and re-emerging infectious diseases like Zika, Ebola, and diseases such as tick-borne encephalitis. This presents lucrative opportunities.

Impact of COVID-19 on Adult Vaccines Market Growth

Fastest Growing Region for Adult Vaccines Market

Various regional governments foresee adult vaccination as a strategic national priority to curb the impact of communicable as well as non-communicable diseases. They offer specific funding and policy impetus for procurement and distribution of vaccines. Growing medical tourism also supplements the regional market growth. Increased penetration of private sector players further drives vaccine awareness and uptake. It is expected that widespread recommendations from healthcare providers and continuous medical education programs will augment adult vaccination rates across Asia Pacific over the coming years.